• 1
    Sarma AV, Jacobson DJ, McGree ME, Roberts RO, Lieber MM, Jacobsen SJ. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 2005; 173: 204853.
  • 2
    Glasser DB, Carson CI, Kang J, Laumann EO. Prevalence of storage and voiding symptoms among men aged 40 years and older in a US population-based study: results from the the Male Attitudes Regarding Sexual Health study. Int J Clin Pract 2007; 61: 1294300.
  • 3
    Cheung WW, Khan NH, Choi KK, Bluth MH, Vincent MT. Prevalence, evaluation and management of overactive bladder in primary care. BMC Fam Pract 2009; 10: 8.
  • 4
    Townsend MK, Curhan GC, Resnick NM, Grodstein F. The incidence of urinary incontinence across Asian, black, and white women in the United States. Am J Obstet Gynecol 2010; 202: 378, e1e7.
  • 5
    Kawabe K, Moriyama N, Yamada S, Taniguchi N. Rationale for the use of α-blockers in the treatment of benign prostatic hyperplasia (BPH). Int J Urol 1994; 1: 20311.
  • 6
    Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002; 19: 3906.
  • 7
    Andersson KE. Muscarinic receptor antagonists for treatment of overactive bladder. Lancet Neurol 2004; 3: 4653.
  • 8
    Ouslander JG. Management of overactive bladder. N Engl J Med 2004; 350: 78699.
  • 9
    Honda K, Miyata-Osawa A, Takenaka T. Alpha 1-Adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. Naunyn Schmiedebergs Arch Pharmacol 1985; 330: 1621.
  • 10
    Yamagishi R, Akiyama K, Nakamura S, Hora M, Masuda N, Matsuzawa A, Murata S, Ujiie A, Kurashina Y, Iizuka K, Kitazawa M. Effect of KMD-3213, an alpha 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol 1996; 315: 739.
  • 11
    Suzuki Y, Kanada A, Okaya Y, Aisaka K, Muramatsu I. Effect of JTH-601, a novel alpha1-adrenoceptor antagonist, on the function of lower urinary tract and blood pressure. Eur J Pharmacol 1999; 374: 495502.
  • 12
    Akiyama K, Hora M, Tatemichi S, Masuda N, Nakamura S, Yamagishi R, Kitazawa M. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 1999; 291: 8191.
  • 13
    Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo RR Jr. International Union of Pharmacology X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 1995; 47: 26770.
  • 14
    Michel MC, Kenny B, Schwinn DA. Classification of alpha 1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 110.
  • 15
    Michel MC, Vrydag W. α1-, α2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147: S88S119.
  • 16
    Farrall AJ, Wardlaw JM. Blood-brain-barrier: ageing and microvascular disease: systematic review and meta-analysis. Neurobiol Aging 2009; 30: 33752.
  • 17
    Flicker C, Ferris SH, Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology 1992; 107: 43741.
  • 18
    Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, Sunderland T. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 1992; 17: 21526.
  • 19
    Norbury R, Travis MJ, Erlandsson K, Waddington W, Owens J, Ell PJ, Murphy DG. SPET imaging of central muscarinic receptors with (R,R)[123I]-I-QNB: methodological considerations. Nucl Med Biol 2004; 31: 58390.
  • 20
    Yamada S, Suzuki M, Kato Y, Kimura R, Mori R, Matsumoto K, Maruyama M, Kawabe K. Binding characteristics of naftopidil and a1-adrenoceptor antagonists to prostatic a-adrenoceptors in benign prostatic hypertrophy. Life Sci 1992; 50: 12735.
  • 21
    Yamada S, Tanaka C, Kimura R, Kawabe K. Alpha 1-adrenoceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists. Life Sci 1994; 54: 1845 -54.
  • 22
    Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S. Human muscarinic receptor binding characteristics of muscarinic receptor antagonists to treat overactive bladder. J Urol 2006; 175: 3659.
  • 23
    Yoshida A, Fujino T, Maruyama S, Ito Y, Taki Y, Yamada S. Bladder selectivity based on in vivo drug-receptor binding characteristics of muscarinic receptor antagonists for treatment of overactive bladder. J Pharmacol Sci 2010; 112: 14250.
  • 24
    Yazawa H, Takanashi M, Sudoh K, Inagaki O, Honda K. Characterization of [3H]YM617, R-(-)-5[2[[2]ethoxyring(n)-3H](o-ethoxyphenoxy)ethyl]amino]-propyl]-2-methoxybenzenesulfonamide HCl, a potent and selective alpha-1 adrenoceptor radioligand. J Pharmacol Exp Ther 1992; 263: 2016.
  • 25
    Yamada S, Ohkura T, Kimura R, Kawabe K. In vivo receptor binding of novel α1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia. Life Sci 1998; 62: 15859.
  • 26
    Ohkura T, Yamada S, Deguchi Y, Kimura R. Comparative study on pharmacokinetics and in vivo α1-adrenoceptor binding of [3H]tamsulosinand [3H]prasorin in rats. Biol Pharm Bull 1999; 22: 4127.
  • 27
    Yamada S, Ohkura T, Deguchi Y, Kimura R. In vivo measurement by [3H]tamsulosin of α1- adrenoceptors in rat tissues in relation to the pharmacokinetics. J Pharmacol Exp Ther 1999; 289: 157583.
  • 28
    Yamada S, Okura T, Kimura R. In vivo demonstration of α1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther 2001; 296: 1607.
  • 29
    Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther 1997; 282: 22835.
  • 30
    Testa R, Guarneri L, Ibba M, Strada G, Poggesi E, Taddei C, Simonazzi I, Leonardi A. Characterization of alpha 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur J Pharmacol 1993; 249: 30715.
  • 31
    Lepor H, Zhang W, Kobayashi S, Tang R, Wang B, Shapiro E. A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates. J Pharmacol Exp Ther 1994; 270: 7227.
  • 32
    Shibata K, Foglar R, Horie K, Obika K, Sakamoto A, Ogawa S, Tsujimoto G. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 1995; 48: 2508.
  • 33
    Michel MC, Büscher R, Kerker J, Kraneis H. Erdbrügger W, Brodde OE. Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 38595.
  • 34
    Ohkura T, Yamada S, Deguchi Y, Kimura R, Matsushima H, Higuchi S, Inagaki O, Honda K, Takenaka T. Ex vivo occupancy by tamsulosin of α1-adrenoceptors in rat tissues in relation to the plasma concentration. Life Sci 1998; 63: 214755.
  • 35
    Ohukura T, Yamada S, Abe Y, Kimura R. Selective and sustained occupancy of prostatic α1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats. J Pharm Pharmacol 2002; 54: 97582.
  • 36
    Michel MC, Goepel M. Differential α1-adrenoceptor labeling by [3H]prazosin and [3H]tamsulosin. Eur J Pharmacol 1998; 342: 8592.
  • 37
    Aboud R, Shafii M, Docherty JR. Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. Br J Pharmacol 1993; 109: 807.
  • 38
    Kenny BA, Chalmers DH, Philpott PC, Naylor AM. Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol 1995; 115: 9816.
  • 39
    Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol 1997; 120: 2318.
  • 40
    Taguchi K, Saitoh M, Sato S, Asano M, Michel MC. Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther 1997; 280: 15.
  • 41
    Murata S, Taniguchi T, Muramatsu I. Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand. Br J Pharmacol 1999; 127: 1926.
  • 42
    Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 24362.
  • 43
    Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999; 161: 180912.
  • 44
    Davila GW, Daugherty CA, Sanders SW; Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 1405.
  • 45
    Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW; Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 23742.
  • 46
    Oki T, Toma-Okura A, Yamada S. Advantages for transdermal over oral oxybutynin to treat overactive bladder: muscarinic receptor binding, plasma drug concentration, and salivary secretion. J Pharmacol Exp Ther 2006; 316: 113745.
  • 47
    Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997; 57: 10937.
  • 48
    Oki T, Kawashima A, Uchida M, Yamada S. In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin. Life Sci 2005; 76: 244556.
  • 49
    Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine – a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195207.
  • 50
    Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 16972.
  • 51
    Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26: 28993.
  • 52
    Oki T, Sato S, Miyata K, Yamada S. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br J Pharmacol 2005; 145: 21927.
  • 53
    Oki T, Maruyama S, Takagi Y, Yamamura HI, Yamada S. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. Eur J Pharmacol 2006; 529: 15763.
  • 54
    Maruyama S, Hasuike N, Suzuki K, Yamada S. In vivo characteriation of muscarinic receptos in peripheral tissues: evaluation of bladder selectivity of muscarinic receptor antagonists to treat overactive bladder. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 46371.
  • 55
    Påhlman I, d'Argy R, Nilvebrant L. Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice. Arzneimittelforschung 2001; 51: 12533.
  • 56
    Stöhrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia – a double-blind, placebo-controlled clinical trial. Spinal Cord 1999; 37: 196200.
  • 57
    Madersbacher H, Halaska M, Voigt R, Alloussi S, Höfner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999; 84: 64651.
  • 58
    Oki T, Yamada S, Toma A, Kimura R. Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine. Biol Pharm Bull 2001; 24: 4915.
  • 59
    Ito Y, Kato A, Fujino-Oki T, Okura T, Yoshida K, Nanri M, Yamada S. Muscarinic receptor binding and plasma drug concentration after the oral administration of propiverine in mice. LUTS 2010; 2: 439.
  • 60
    Yamada S, Ito Y, Taki Y, Seki M, Nanri M, Yamashita F, Morishita K, Komoto I, Yoshida K. The N-oxide metabolite contributes to bladder selectivity due to oral propiverine: muscarinic receptor binding and pharmacokinetics. Drug Metab Dis 2010; 38: 131421.
  • 61
    Kobayashi F, Yageta Y, Segawa M, Matsuzawa S. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 2007; 57: 92100.
  • 62
    Kobayashi F, Yageta Y, Yamazaki T, Wakabayashi E, Inoue M, Segawa M, Matsuzawa S. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittel forschung 2007; 57: 14754.
  • 63
    Homma Y, Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008; 15: 98691.
  • 64
    Homma Y, Yamaguchi O; Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009; 16: 499506.
  • 65
    Yamada S, Seki M, Ogoda M, Furuta A, Nakamura M, Ito Y. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agents, imidafenasin, to treat overactive bladder. J Pharmacol Exp Ther 2011; 336: 36571.
  • 66
    Kornblum HI, Araujo DM, Annala AJ, Tatsukawa KJ, Phelps ME, Cherry SR. In vivo imaging of neuronal activation and plasticity in the rat brain by high resolution positron emission tomography (microPET). Nat Biotech 2000; 18: 65560.
  • 67
    Mizuta T, Kitamura K, Iwata H, Yamagishi Y, Ohtani A, Tanaka K, Inoue Y. Performance evaluation of a high-sensitivity large-aperture small-animal PET scanner: ClairvivoPET. Ann Nucl Med 2008; 22: 44755.
  • 68
    Tsukada H. Delivery of radioligands for positron emission tomography (PET) in the central nervous system. Adv Drug Deliv Rev 1999; 37: 17588.
  • 69
    Halldin C, Gulyas B, Farde L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des 2001; 7: 190729.
  • 70
    Yoshida Y, Maruyama S, Fukumoto D, Tsukada H, Ito Y, Yamada S. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. Life Sci 2010; 25: 17580.
  • 71
    Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 813.
  • 72
    Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332: 45559.
  • 73
    Maruyama S, Tsukada H, Nishiyama S, Kakiuchi T, Fukumoto D, Oku N, Yamada S. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by muscarinic receptor antagonists for overactive bladder treatment. J Pharmacol Exp Ther 2008; 325: 77481.
  • 74
    Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol 2007; 177: 76670.
  • 75
    Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, Steel M. Differential effects of the muscarinic receptor antagonists darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 31726.
  • 76
    Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur J Pharmacol 2007; 557: 15458.
  • 77
    Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005; 27: 14453.
  • 78
    Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001; 18: 277304.
  • 79
    Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006; 45: 32550.
  • 80
    Oki T, Takagi Y, Inagaki S, Taketo MM, Manabe T, Matsui M, Yamada S. Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Res Mol Brain Res 2005; 133: 611.
  • 81
    Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriat Soc 2005; 53: 2195201.
  • 82
    Yamada S, Maruyama S, Takagi Y, Uchida S, Oki T. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. Life Sci 2006; 80: 12732.
  • 83
    Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S. Comparison of muscarinic selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol 2009; 615: 2016.
  • 84
    Birder LA, Ruan HZ, Chopra B, Xiang Z, Barrick S, Buffington CA, Roppolo JR, Ford AP, de Groat WC, Burnstock G. Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis. Am J Physiol Renal Physiol 2004; 287: F108491.
  • 85
    Giglio D, Ryberg AT, To K, Delbro DS, Tobin G. Altered muscarinic receptor subtype expression and functional responses in cyclophosphamide induced cystitis in rats. Auton Neurosci 2005; 122: 920.
  • 86
    Kageyama A, Fujino T, Taki Y, Kato Y, Nozawa Y, Ito Y, Yamada S. Alteration of muscarinic and purinergic receptors in urinary bladder of rats with cyclophosphamide-induced interstitial cystitis. Neurosci Lett 2008; 436: 814.
  • 87
    Yoshida A, Kageyama A, Fujino T, Nozawa Y, Yamada S. Loss of muscarinic and purinergic receptors in the urinary bladder of rats with hydrochloric acid-induced cystitis. Urol 2010; 76: 1017, e7e12.
  • 88
    Ito Y, Oyunzul L, Seki M, Fujino-Oki T, Matsui M, Yamada S. Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 single subtype knockout mice. Br J Pharmacol 2009; 156: 114753.